Snapinn, Steven M.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 7,493

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet

Blood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

Cited by 1,560

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 539

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 392